ABCL Q4 2020 Earnings — AbCellera Biologics Inc. Revenue & Financial Results | Market Cap Arena

ABCLAbCellera Biologics Inc.

$1B

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$208M+6392.3% YoY

Gross Profit

$00.0% margin

Operating Income

$161M77.3% margin

Net Income

$117M56.3% margin

EPS (Diluted)

$0.37

QoQ Revenue Growth

+2120.8%

Cash Flow

Operating Cash Flow

$2M

Free Cash Flow

-$22,510

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$1.0B

Total Liabilities

$175M

Stockholders' Equity

$831M

Cash & Equivalents

$594M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$208M	$3M	+6392.3%
Gross Profit	$0	$0	—
Operating Income	$161M	-$2M	+8236.2%
Net Income	$117M	-$2M	+7229.9%